CN114632037A - 一种修护舒缓面膜组合物、冻干面膜及其制备方法 - Google Patents
一种修护舒缓面膜组合物、冻干面膜及其制备方法 Download PDFInfo
- Publication number
- CN114632037A CN114632037A CN202111640276.2A CN202111640276A CN114632037A CN 114632037 A CN114632037 A CN 114632037A CN 202111640276 A CN202111640276 A CN 202111640276A CN 114632037 A CN114632037 A CN 114632037A
- Authority
- CN
- China
- Prior art keywords
- mask
- freeze
- percent
- dried
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 34
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 30
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 30
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 30
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 17
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 15
- 229930195725 Mannitol Natural products 0.000 claims abstract description 15
- 239000000594 mannitol Substances 0.000 claims abstract description 15
- 235000010355 mannitol Nutrition 0.000 claims abstract description 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102000008186 Collagen Human genes 0.000 claims abstract description 14
- 108010035532 Collagen Proteins 0.000 claims abstract description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 14
- 229920001436 collagen Polymers 0.000 claims abstract description 14
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 14
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 14
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 14
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 11
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 9
- 229960000458 allantoin Drugs 0.000 claims abstract description 9
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- 238000004458 analytical method Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 5
- 230000001815 facial effect Effects 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000004744 fabric Substances 0.000 claims description 17
- 239000008367 deionised water Substances 0.000 claims description 16
- 229910021641 deionized water Inorganic materials 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 13
- 229940119217 chamomile extract Drugs 0.000 claims description 8
- 235000020221 chamomile extract Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229940064064 purslane extract Drugs 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 3
- 102000001187 Collagen Type III Human genes 0.000 claims description 2
- 108010069502 Collagen Type III Proteins 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000000246 remedial effect Effects 0.000 claims 3
- 244000146462 Centella asiatica Species 0.000 claims 1
- 235000004032 Centella asiatica Nutrition 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 239000002994 raw material Substances 0.000 abstract description 12
- 239000003755 preservative agent Substances 0.000 abstract description 6
- 230000002335 preservative effect Effects 0.000 abstract description 5
- 230000007794 irritation Effects 0.000 abstract 1
- 238000002061 vacuum sublimation Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 15
- 239000000686 essence Substances 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000008439 repair process Effects 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 239000002985 plastic film Substances 0.000 description 4
- 229920006255 plastic film Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- -1 parabens Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种修护舒缓面膜组合物、冻干面膜及其制备方法,面膜组合物包括功效组分和辅料,所述功效组分按照终浓度的组成包括:重组人源胶原蛋白0.50%‑3.0%、寡肽‑1 0.20%‑0.40%、寡肽‑3 0.20%‑0.40%、积雪草提取物0.10%‑0.50%、尿囊素0.30%‑0.50%;所述辅料按照终浓度的组成包括:甘露糖醇1.0%‑4.0%、海藻糖2.0%‑3.0%、分子量8000道尔顿的透明质酸钠0.15%‑0.30%、分子量130万道尔顿的透明质酸钠0.15%‑0.30%、磷酸氢二钠0.16%‑0.20%、磷酸二氢钠0.09%‑0.16%、甘油1.0%‑3.0%。本发明通过将面膜溶液预冷后进行真空升华干燥步骤,最后再进行解析干燥步骤,保证了面膜中功效原料的活性,同时不添加防腐剂,降低其带来的刺激,真正做到绿色健康。
Description
技术领域
本发明涉及化妆品技术领域,具体涉及一种修护舒缓面膜组合物、冻干面膜及其制备方法。
背景技术
随着城市工作生活节奏加快,熬夜、饮食不规律、过度使用美妆产品、环境问题等使得年轻人更早开始面对皮肤健康问题。“问题肌肤”人群扩大,针对敏感肌、皮损性肌肤等修护类化妆品成为护肤市场热点品类。在我国,越来越多的消费者更加关注对当下敏感肌问题和皮肤风险的解决。经统计,各大购物平台中“修复”“敏感肌”等关键词的相关搜索数在各类护肤主流需求中排名突出,高于美白、控油、抗衰、抗皱等传统化妆品功效需求。其关注度较过去显著提升,由此带动修复类护肤品需求爆发,安全性、专业性、针对性突出的产品愈受青睐。
面膜是一种广泛应用的护肤产品。精华液中类似胶原蛋白和寡肽的关键活性原料由于出色的功效受到了广大消费者的欢迎,与此同时,它们大多也存在对热不稳定、易氧化、易降解等缺点。目前大部分面膜精华液从生产到使用都处在液体状态,里面许多较高生物活性的原料在水活度高的体系里会降解或效力衰减,无法发挥其完整生物效应。另外,为了让富含营养物质的精华液可以长时间储存,其中会添加一些如醇类、对羟基苯甲酸酯类、甲醛释放体类、甲基氯异噻唑啉酮类或甲基异噻唑啉酮类的防腐剂,进而增加过敏或诱发接触性皮肤炎的几率。
除了活性原料,面膜布亦是影响面膜整体品质的关键因素,并成为不少面膜产品发展的瓶颈。传统的保湿面膜通常是采用面膜精华液灌装入装有灭菌面膜布的铝塑袋子里,然后密封包装的形式进行销售。消费者在使用前撕开面膜的密封包装,直接将浸透精华液的面膜布敷于脸部,待15-20分钟,精华液吸收完毕后摘掉面膜布即可。但值得注意的是,面膜布仅仅是精华液的载体,其材质会严重影响附着的营养成分的透皮吸收率。传统的无纺布面膜尤其是纯棉材质的,虽然承载的精华液比较多,敷感柔润舒服,密封性优良,价格低廉,但其透气性一般,精华液不够时会翘起不服帖,与皮肤的亲和力不佳,织布材质的面膜布敷得过久时甚至会吸收皮肤表面的水分;另外,无纺布的生产过程容易产生化学物质残留,脱落的织物残留还会刺激皮肤,诱发瘙痒过敏的症状,被丢弃后的布料还会污染环境。蚕丝面膜主要的原材料就是蚕丝纤维和活性蚕丝蛋白,其本身就含有对人体极具营养价值的氨基酸,而且比无纺布更轻更薄,贴合度、透气性更好,然而,蚕丝面膜对精华液的承载能力有限,其拉伸性很差,容易破损,而且原材料成本也比较高,因此市面上的蚕丝面膜会混杂“真蚕丝面膜”和“蚕丝工艺面膜”,品质参差不齐。虽然最新的纤维素面膜大大提升了产品质感,但其成本也有大幅度的上升。鉴于以上问题,冻干面膜确实是不错的选择,但是,当前冻干面膜的普遍做法是将面膜布浸泡在精华液中,经过冷冻干燥、裁剪后得出成品,除了增加整体成本之外,仍然存在面膜布对品质造成影响的风险。
因此,需要探索出一种方便储存、高活性、易使用的修护舒缓冻干面膜,喷水即用,减少面膜布对面膜品质的不良影响。在保证安全性的同时减少资源浪费,达到“用户友好”和“环境友好”的目的。
发明内容
有鉴于此,有必要针对的问题,提供一种修护舒缓面膜组合物、冻干面膜及其制备方法。本发明的技术方案为:
第一方面,本发明提供一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:重组人源胶原蛋白0.5%-3.0%、寡肽 -1 0.20%-0.40%、寡肽-3 0.20%-0.40%、积雪草提取物0.10%-0.50%、尿囊素 0.30%-0.50%;所述辅料按照终浓度的组成包括:甘露糖醇1.0%-4.0%、海藻糖 2.0%-3.0%、分子量8000道尔顿的透明质酸钠0.15%-0.30%、分子量130万道尔顿的透明质酸钠0.15%-0.30%、磷酸氢二钠0.16%-0.20%、磷酸二氢钠 0.09%-0.16%、甘油1.0%-3.0%,溶剂为去离子水。
优选地,所述重组人源胶原蛋白为重组人源III型胶原蛋白;
优选地,所述积雪草提取物中积雪草总苷含量高达90%以上。
进一步地,所述功效组分还可以替换成:六胜肽0.50%-2.0%、五胜肽 0.30%-1.5%、洋甘菊提取物0.30%-1.3%,马齿苋提取物0.1%-1.0%。
优选地,所述组合物中,所述功效组分按照终浓度的组成包括:重组人源 III型胶原蛋白2.0%、寡肽-1 0.30%、寡肽-3 0.30%、积雪草提取物0.30%,尿囊素0.40%;所述辅料按照终浓度的组成包括:甘露糖醇2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130万道尔顿的透明质酸钠0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.10%、甘油2.0%,溶剂为去离子水。
优选地,所述组合物中,所述功效组分按照终浓度的组成包括:六胜肽1.1%、五胜肽0.90%、洋甘菊提取物0.60%、马齿苋提取物0.50%;所述辅料按照终浓度的组成包括:甘露糖醇2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130万道尔顿的透明质酸钠0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.11%、甘油2.0%,溶剂为去离子水。
第二方面,本发明一种修护舒缓冻干面膜的制备方法,包括以下步骤:
步骤1,按照上述组合物的功效组分和辅料的成分组成配料;
步骤2,将辅料的所有成分在去离子水中,于75~85℃、400~600rpm条件下搅拌10~15min;
步骤3,将步骤2获得的溶液进行高压灭菌;
步骤4,将高压灭菌后的溶液中加入功效组分的所有成分,于30~40℃、 400~600rpm条件下搅拌10~15min;
步骤5,将步骤4的溶液进行滤布初滤,再用微孔滤膜过滤,得到面膜溶液;
步骤6,将面膜溶液采用面膜模具进行冻干操作;
步骤7,将获得冻干面膜剥离面膜模具,即得。
优选地,所述步骤3所述的高压灭菌温度为120~125℃,时间为25~35min;
优选地,所述步骤5所述的滤布的孔径为100目;
优选地,所述步骤5所述的微孔滤膜孔径为0.22μm;
优选地,所述步骤6所述的面膜模具采用硅胶面膜模具;
优选地,所述步骤6所述的面膜模具以标准脸型设计多个尺寸,包括①内部尺寸:19*20.8cm;②内部尺寸:19.5*22cm;③内部尺寸:20.1*23.4cm;④内部尺寸:20.7*24.3cm;
优选地,所述步骤6所述的面膜溶液灌装入面膜模具的液体高度为3mm;
优选地,为了使面膜与面膜模具更易分离,将面膜溶液灌装入面膜模具之前,在面膜模具上放置与面膜模具尺寸一致、厚度为12.5mic的聚乙烯塑料薄膜;
优选地,所述步骤6冻干操作的具体控制过程为:常压下,先梯度降温至 -45~-40℃,降温速率为35~40℃/h,保温3-4h进行预冷;将气压从常压降到 10~20Pa;于6~9h内梯度升温至0~10℃,升温速率为5~10℃/h,保温2~2.5h;再进行解析干燥,将气压降到0~10Pa,进一步升温至15~20℃,保温4~6h。
第三方面,本发明提供一种冻干面膜,是采用上述制备方法获得。
本发明的有益效果:
1.本发明所述的修护舒缓面膜组合物及冻干面膜,能够促进上皮再生,形成具有良好弹性的软组织;促进成纤维细胞和内皮细胞往伤口的迁移,增加微血管密度,甚至可以减少伤口处的细菌总数;还具有表皮修复、保湿抗氧化、消炎抗菌、舒缓抗敏的作用。
2.本发明所述的冻干面膜利用医药领域常用的冷冻干燥技术,保证了面膜中功效原料的活性,同时不添加防腐剂,降低其带来的刺激,真正做到绿色健康;并且制备过程中修护舒缓冻干面膜溶液经充分搅拌后灌注,保证了面膜中功效原料能够分布均匀,更利于面部的均匀吸收;此外,本发明的冻干面膜方便携带,易使用。使用前将塑料膜撕掉,将面膜贴紧面部后,可根据个人喜好和需求把喷雾、精华、纯水、化妆水等溶媒均匀喷洒到面膜上,使皮肤能更直接地吸收到面膜中的精华成分。
具体实施方式
在本发明的描述中,需要说明的是,实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
下面结合具体的实施例对本发明做进一步详细说明,所述是对本发明的解释而不是限定。
实施例1
一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:重组人源Ⅲ型胶原蛋白0.50%、寡肽-1 0.20%、寡肽-3 0.20%、积雪草提取物0.10%、尿囊素0.30%;所述辅料按照终浓度的组成包括:甘露糖醇1.0%、海藻糖2.0%、分子量8000道尔顿的透明质酸钠0.15%、分子量130 万道尔顿的透明质酸钠0.15%、磷酸氢二钠0.16%、磷酸二氢钠0.09%、甘油1.0%,溶剂为去离子水。
本实施例提供了一种修护舒缓冻干面膜的制备方法,包括以下步骤:
步骤1,按照上述组合物的功效组分和辅料的成分组成配料;
步骤2,将辅料的所有成分在去离子水中,于80℃、450rpm条件下搅拌10min;
步骤3,将步骤2获得的溶液在121℃的下进行高压灭菌30min;
步骤4,将高压灭菌后的溶液中加入功效组分的所有成分,于35℃、 400~600rpm条件下搅拌15min;
步骤5,将步骤4的溶液用100目的滤布进行初滤,再用0.22μm微孔滤膜过滤后存放于无菌密封容器中,得到面膜溶液;
步骤6,将面膜溶液采用面膜模具进行冻干操作;冻干操作的具体控制过程为:常压下,先快速降温至-42℃,降温速率为40℃/h,保温4h进行预冷;将气压从常压降至15Pa,于8h内梯度升温至8℃,升温速率为6.5℃/h,保温2.5h;再进行解析干燥,将气压降至5Pa,进一步升温至16℃,保温5.5h。
为了使面膜与面膜模具更易分离,将面膜灌装入面膜模具之前,在面膜模具上放置与面膜模具尺寸一致、厚度为12.5mic的聚乙烯塑料薄膜;面膜溶液灌装入面膜模具的液体高度为3mm;
步骤7,将获得冻干面膜剥离面膜模具,在无菌环境下装袋封口,即得。
实施例2
一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:重组人源Ⅲ型胶原蛋白3.0%、寡肽-1 0.40%、寡肽-3 0.40%、积雪草提取物0.50%、尿囊素0.50%;所述辅料按照终浓度的组成包括:甘露糖醇4.0%、海藻糖3.0%、分子量8000道尔顿的透明质酸钠0.30%、分子量130 万道尔顿的透明质酸钠0.30%、磷酸氢二钠0.20%、磷酸二氢钠0.12%、甘油3.0%,溶剂为去离子水。
本实施例中提供了一种修护舒缓冻干面膜的制备方法,步骤同实施例1。
实施例3
一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:重组人源Ⅲ型胶原蛋白2.0%、寡肽-1 0.30%、寡肽-3 0.30%、积雪草提取物0.30%、尿囊素0.40%;所述辅料按照终浓度的组成包括:甘露糖醇2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130 万道尔顿的透明质酸钠0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.10%、甘油2.0%,溶剂为去离子水。
本实施例中提供了一种修护舒缓冻干面膜的制备方法,步骤同实施例1。
实施例4
一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:六胜肽0.50%、五胜肽0.30%、洋甘菊提取物0.30%、马齿苋提取物0.10%;所述辅料按照终浓度的组成包括:甘露糖醇1.0%、海藻糖2.0%、分子量8000道尔顿的透明质酸钠0.15%、分子量130万道尔顿的透明质酸钠0.15%、磷酸氢二钠0.16%、磷酸二氢钠0.09%、甘油1.0%,溶剂为去离子水。
本实施例中提供了一种修护舒缓冻干面膜的制备方法,步骤同实施例1。
实施例5
一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:六胜肽2.0%、五胜肽1.5%、洋甘菊提取物1.3%、马齿苋提取物1.0%;所述辅料按照终浓度的组成包括:甘露糖醇4.0%、海藻糖3.0%、分子量8000道尔顿的透明质酸钠0.30%、分子量130万道尔顿的透明质酸钠 0.30%、磷酸氢二钠0.20%、磷酸二氢钠0.13%、甘油3.0%,溶剂为去离子水。
本实施例中提供了一种修护舒缓冻干面膜的制备方法,步骤同实施例1。
实施例6
一种修护舒缓冻干面膜组合物,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:六胜肽1.1%、五胜肽0.90%、洋甘菊提取物0.60%、马齿苋提取物0.50%;所述辅料按照终浓度的组成包括:甘露糖醇2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130万道尔顿的透明质酸钠 0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.11%、甘油2.0%,溶剂为去离子水。
本实施例中提供了一种修护舒缓冻干面膜的制备方法,步骤同实施例1。
对比例1
一种修护舒缓冻干面膜组合物,其组分按照终浓度的组成包括:甘露糖醇 2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130万道尔顿的透明质酸钠0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.10%、甘油2.0%,溶剂为去离子水。
与实施例3相比不同之处在于,对比例1未添加功效组分。
效果验证
一、皮肤水分及试用感受测试
实验时用德国CK公司Corneometer CM825皮肤水分测试仪测试每名受试者的皮肤含水量。皮肤水分的测试原理是基于水(81)和其他物质的介电常数 (<7)有显著的差距,电容器测量时会随着皮肤电容量的变化而变化,而皮肤的电容量亦是在测量的范围内的原理,测量出皮肤的水分含量。
随机挑选90名敏感性肌肤且有过敏现象的受试者,平均分为9组,每组10 人。将6个实施例,1个对比例和市面上销售的2种舒缓面膜对应分给各组受试者使用,要求受试者在面部试用时将纯水均匀喷洒到面膜上,15分钟后用纸巾擦拭面部进行清理。试用时间为15天,每一次试用前后均要测试皮肤含水量,每隔2天试用一次。在温度为25℃,相对湿度为45%的环境下对受试者面部的皮肤水分含量进行测试,计算每组的平均水分含量,然后代入以下公式计算受试者皮肤含水量的增长率,结果见表1。
另外,15天后收集受试者就面膜褪红效果、止痒效果和肤感进行评分的结果,“0”分最差,“10”分最佳,评价结果记录见表2。
表1受试者皮肤含水量增长率(%)
表2受试者舒敏功效和肤感的测试结果
二、创面修复测试
购置健康大鼠45只,随机分成9组,每组5只。5只一笼进行饲养,自由饮水饮食。在温度为25℃,湿度为45%的饲养环境下喂养一周后,按照15mL/kg 的注射量向大鼠腹腔注射0.3%苯巴比妥钠。等待10min,大鼠完全昏迷后,用脱毛膏将其背部脱毛。用直径为1.5cm的不锈钢打孔器在其背部脱毛处打下两个面积约为1.77cm2,深度约为2mm的小孔(每只大鼠2处创面,左背、右背各1处),建立皮肤创伤动物模型。
以6个实施例,1个对比例和市面上销售的两种舒缓面膜对应标记各个分组,取相应组别的冻干面膜样品,裁剪成3cm×3cm的正方形小块,覆盖在小鼠背部创口上并喷洒生理盐水使其均匀湿透。待15min后,用无菌纱布清洁创口,并用单层无菌纱布覆盖创口。每天处理1次,观察并记录创口变化,再通过Image J软件计算出创面愈合百分率。结果见表3。
表3样品处理后创面愈合百分率(%)
结合表1、表2和表3的结果可知,按照本发明的实施例制得的冻干面膜均有修护和舒缓的功能,同时具有良好的保湿、滋养皮肤的效果。市售舒缓面膜的配方内缺少修护成分,虽然能发挥一定的舒敏效果,但在促创面修复上的作用并不出色。而根据实施例1和实施例2或者实施例4和实施例5的对比得知,加入更多的辅料和功效组份能使面膜的保湿、舒缓和促修复性能更为出色。但随之而来的问题是,浓度过高的组份会使体系变的粘稠,严重影响肤感,由表2 可以看出,实施例2和实施例5的肤感评分不高。因此,经综合评估后可知,本发明中实施例3和实施例6的方案功效性较强,肤感较好,更为优越。
综上所述,本发明的面膜组合物及冻干面膜具有以下功效:
1.本发明所述的修护舒缓冻干面膜,采用高低分子透明质酸钠(Hyaluronicacid,以下简称“HA)”,HA能通过减少炎症介导的细胞凋亡来减轻乙醇诱导的细胞毒性,而且HA在伤口愈合和疤痕形成的生理过程发挥着重要的作用。其能促进上皮再生,形成具有良好弹性的软组织;促进成纤维细胞和内皮细胞往伤口的迁移,增加微血管密度,甚至可以减少伤口处的细菌总数,其中较高分子量的HA有助于伤口愈合,较低分子量的HA有助于减少愈合过程中瘢痕组织的增生;
2.本发明所述的功效组分中寡肽-1、寡肽-3、重组人源Ⅲ型胶原蛋白,起到刺激胶原蛋白合成,促进表皮修复,保湿抗氧化的作用;积雪草提取物可有效促进皮肤损伤、局部胶原合成代谢,并在皮肤损伤后的组织修复方面有中药作用;积雪草提取物、尿囊素、洋甘菊提取物和马齿苋提取物能起到消炎抗菌、舒缓抗敏的辅助效果;
3.本发明所述的修护舒缓冻干面膜溶液经充分搅拌后灌注,保证了面膜中功效原料能够分布均匀,更利于面部的均匀吸收;
4.本发明所述的冻干面膜利用医药领域常用的冷冻干燥技术,保证了面膜中功效原料的活性,同时不添加防腐剂,降低其带来的刺激,真正做到绿色健康;
5.本发明所述的冻干面膜,直接采用透明质酸钠、甘露糖醇等功效原料作为面膜的基本辅料,面膜经冷冻干燥后方便携带,易使用。使用前将塑料膜撕掉,将面膜贴紧面部后,可根据个人喜好和需求把喷雾、精华、纯水、化妆水等溶媒均匀喷洒到面膜上,使皮肤能更直接地吸收到面膜中的精华成分。
6.由于面膜液加入的物料比较多,饱和度比较大。本次冻干的预冷过程采用速冻的方式,加快成核速度,使细晶的体积尽量减小,内含粒子更加细腻,减少结构空隙,让面膜外观更加均匀。梯度缓慢升温有利于冰晶通过面膜微孔结构的缓慢升华,避免了升华过程对整体结构的破坏。解析干燥阶段通过进一步减低真空度和提高温度的方式,为产品中吸附水的解析提供了足够的能量,而且高真空形成的较大蒸汽压差也可使解析出来的水蒸气有足够的推动力逸出产品。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种修护舒缓冻干面膜组合物,其特征在于,包括功效组分和辅料,所述功效组分按照终浓度的组成包括:重组人源胶原蛋白0.50%-3.0%、寡肽-10.20%-0.40%、寡肽-30.20%-0.40%、积雪草提取物0.10%-0.50%,尿囊素0.30%-0.50%;所述辅料按照终浓度的组成包括:甘露糖醇1.0%-4.0%、海藻糖2.0%-3.0%、分子量8000道尔顿的透明质酸钠0.15%-0.30%、分子量130万道尔顿的透明质酸钠0.15%-0.30%、磷酸氢二钠0.16%-0.20%、磷酸二氢钠0.09%-0.16%、甘油1.0%-3.0%;溶剂为去离子水。
2.根据权利要求1所述的修护舒缓冻干面膜组合物,其特征在于,所述的重组人源胶原蛋白为重组人源III型胶原蛋白。
3.根据权利要求1所述的修护舒缓冻干面膜组合物,其特征在于,所述的积雪草提取物中积雪草总苷含量高达90%以上。
4.根据权利要求1所述的修护舒缓冻干面膜组合物,其特征在于,所述功效组分还可以替换成:六胜肽0.50%-2.0%、五胜肽0.30%-1.5%、洋甘菊提取物0.30%-1.3%,马齿苋提取物0.10%-1.0%。
5.根据权利要求2所述的修护舒缓冻干面膜组合物,其特征在于,所述功效组分按照终浓度的组成包括:重组人源III型胶原蛋白2.0%、寡肽-1 0.30%、寡肽-3 0.30%、积雪草提取物0.30%,尿囊素0.40%;所述辅料按照终浓度的组成包括:甘露糖醇2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130万道尔顿的透明质酸钠0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.10%、甘油2.0%,溶剂为去离子水。
6.根据权利要求4所述的修护舒缓冻干面膜组合物,其特征在于,所述功效组分按照终浓度的组成包括:六胜肽1.1%、五胜肽0.90%、洋甘菊提取物0.60%,马齿苋提取物0.50%;所述辅料按照终浓度的组成包括:甘露糖醇2.5%、海藻糖2.5%、分子量8000道尔顿的透明质酸钠0.22%、分子量130万道尔顿的透明质酸钠0.20%、磷酸氢二钠0.18%、磷酸二氢钠0.11%、甘油2.0%,溶剂为去离子水。
7.一种修护舒缓冻干面膜的制备方法,其特征在于,包括以下步骤:
步骤1,按照权利要求1~6任意一项所述的组合物的功效组分和辅料的成分组成配料;
步骤2,将辅料的所有成分在去离子水中,于75~85℃、400~600rpm条件下搅拌10~15min;
步骤3,将步骤2获得的溶液进行高压灭菌;
步骤4,将高压灭菌后的溶液中加入功效组分的所有成分,于30~40℃、400~600rpm条件下搅拌10~15min;
步骤5,将步骤4的溶液进行滤布初滤,再用微孔滤膜过滤,得到面膜溶液;
步骤6,将面膜溶液采用面膜模具进行冻干操作;
步骤7,将获得冻干面膜剥离面膜模具,即得。
8.根据权利要求7所述的修护舒缓冻干面膜的制备方法,其特征在于,所述步骤5所述的滤布的孔径为100目,所述的微孔滤膜孔径为0.22μm。
9.根据权利要求8所述的修护舒缓冻干面膜的制备方法,其特征在于,所述步骤6冻干操作的具体控制过程为:常压下,先梯度降温至-45~-40℃,降温速率为35~40℃/h,保温3-4h进行预冷;将气压从常压降到10~20Pa;于6~9h内梯度升温至0~10℃,升温速率为5~10℃/h,保温2~2.5h;再进行解析干燥,将气压降到0~10Pa,进一步升温至15~20℃,保温4~6h。
10.一种冻干面膜,其特征在于,采用权利要求7~9任意一项所述的制备方法获得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111640276.2A CN114632037A (zh) | 2021-12-29 | 2021-12-29 | 一种修护舒缓面膜组合物、冻干面膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111640276.2A CN114632037A (zh) | 2021-12-29 | 2021-12-29 | 一种修护舒缓面膜组合物、冻干面膜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114632037A true CN114632037A (zh) | 2022-06-17 |
Family
ID=81946535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111640276.2A Pending CN114632037A (zh) | 2021-12-29 | 2021-12-29 | 一种修护舒缓面膜组合物、冻干面膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114632037A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106109358A (zh) * | 2016-08-25 | 2016-11-16 | 安迪美生物科技(北京)有限公司 | 一种多肽蚕丝补水修护面膜及其制备方法 |
CN106176282A (zh) * | 2016-08-19 | 2016-12-07 | 山西锦波生物医药股份有限公司 | 蛋白面膜液及生产方法 |
CN111568800A (zh) * | 2020-07-09 | 2020-08-25 | 广州广美依医疗科技有限公司 | 一种含有寡肽的紧致抗衰化妆品 |
CN111743836A (zh) * | 2020-07-08 | 2020-10-09 | 广州暨创医美生物科技有限公司 | 一种舒缓修护面膜液、及其制备方法和包含其的冻干面膜 |
CN112043621A (zh) * | 2020-09-15 | 2020-12-08 | 浙江宜格企业管理集团有限公司 | 一种具有抗衰效果的无防腐多肽组合物 |
CN113041391A (zh) * | 2021-03-31 | 2021-06-29 | 广州源肽生物科技有限公司 | 一种含积雪草-胶原蛋白修复冻干海绵及其制备方法 |
-
2021
- 2021-12-29 CN CN202111640276.2A patent/CN114632037A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176282A (zh) * | 2016-08-19 | 2016-12-07 | 山西锦波生物医药股份有限公司 | 蛋白面膜液及生产方法 |
CN106109358A (zh) * | 2016-08-25 | 2016-11-16 | 安迪美生物科技(北京)有限公司 | 一种多肽蚕丝补水修护面膜及其制备方法 |
CN111743836A (zh) * | 2020-07-08 | 2020-10-09 | 广州暨创医美生物科技有限公司 | 一种舒缓修护面膜液、及其制备方法和包含其的冻干面膜 |
CN111568800A (zh) * | 2020-07-09 | 2020-08-25 | 广州广美依医疗科技有限公司 | 一种含有寡肽的紧致抗衰化妆品 |
CN112043621A (zh) * | 2020-09-15 | 2020-12-08 | 浙江宜格企业管理集团有限公司 | 一种具有抗衰效果的无防腐多肽组合物 |
CN113041391A (zh) * | 2021-03-31 | 2021-06-29 | 广州源肽生物科技有限公司 | 一种含积雪草-胶原蛋白修复冻干海绵及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107496325A (zh) | 含牡丹精油、青瓜提取液和蜗牛原液的面膜及其制备方法 | |
CN107375032B (zh) | 一种修复皮肤屏障的组合物及制备方法 | |
CN104921983A (zh) | 一种孕妇妊娠纹医用生物修复敷料及其制备方法 | |
CN110711150B (zh) | 一种多肽脂质体的制备方法及其应用 | |
CN109044941B (zh) | 一种皮肤紧致滋养保湿组合物及其制备方法和应用 | |
CN108653129B (zh) | 一种包含天然植物抗敏组合物的皮肤敷料 | |
CN113648273A (zh) | 一种利于面部皮肤修复术后恢复的舒缓面膜及其制备方法 | |
CN114259419B (zh) | 一种含重组胶原蛋白的复配组合物及其制备方法和应用 | |
CN109394612A (zh) | 一种补水修复面膜及其制备方法 | |
KR102452905B1 (ko) | 천연 스피큘과 폴리디옥사논을 함유한 피부개선 화장조성물 제조방법 및 그 화장조성물 | |
CN114225007B (zh) | 一种用于修复浅表性创面的乳清蛋白喷雾剂及制备方法 | |
CN105267123A (zh) | 一种美白保湿爽肤水及其制备方法 | |
WO2020244166A1 (zh) | 一种复合生物酶医用修复面膜及其制备方法 | |
CN108815094A (zh) | 一种细胞外基质冻干粉的用途 | |
WO2008080443A2 (en) | Cosmetic composition for the treatment and/or prevention of skin stretch marks | |
CN116850074A (zh) | 一种舒缓保湿皮肤特护乳及其制备方法 | |
CN114632037A (zh) | 一种修护舒缓面膜组合物、冻干面膜及其制备方法 | |
CN110859758A (zh) | 一种美白抗衰老修复型医用冷敷贴及其制备方法 | |
CN114159341B (zh) | 一种冻干眼贴及其制备方法 | |
CN117297996A (zh) | 一种水蛭素冻干面膜及其制备方法 | |
KR101917026B1 (ko) | 피부 주름 개선 또는 예방용 화장료 조성물 | |
CN108785128A (zh) | 一种聚丙二醇修饰的水解胶原蛋白脂质体及其制备方法 | |
CN114146017A (zh) | 一种冻干眼贴及其制备方法 | |
CN111265451A (zh) | 一种蛋白焕颜修护冻干面膜及其制备方法 | |
CN112604027A (zh) | 一种用于全方位解决面部塌陷的营养液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220617 |
|
RJ01 | Rejection of invention patent application after publication |